AU655862B2 - Method for measuring fibrinolytic capacity within whole human plasma - Google Patents

Description

r l-U Y ii i ~111311 OPI DATE 28/06/93 AOJP DATE 02/09/93 APPLN. ID 31424/93 PCT NUMBER PCT/US92/09972 AU9331424 c (51) International Patent Classification 5 C12Q 1/56, G01N 33/86, 33/52 Al (11) International Publication Number: (43) International Publication Date: WO 93/11260 10 June 1993 (10.06.93) (21) International Application Number: PCT/US92/09972 (22) International Filing Date: 20 November 1992 (20.11.92) Priority data: 07/797,564 25 November 1991 (25.11.91) US (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,

SE).

Published With international search report.

(71)Applicant: BAXTER DIAGNOSTICS INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US).

(72) Inventors: DENIS, Rosa, F. 9796 NW 51 Terrace, Miami, FL 33178 RUIZ, Juan, A. 11 Ticonderoga Rd., Acton, MA 01720 (US).

(74) Agents: PEARSON, Louise, S. et al.; One Baxter Parkway, Deerfield, IL 60015 (US).

(54)Title: METHOD FOR MEASURING FIBRINOLYTIC CAPACITY WITHIN WHOLE HUMAN PLASMA (57) Abstract This invention relates to a method for measuring the fibrinolytic capacity of whole plasma. This method comprises coating a solid support with a plasminogen binding material such as polylysine, fibrinogen or fibrin, adding a plasma sample or control and then measuring the amount of plasmin bound to the support. This method is particularly advantageous as the immobilized plasminogen binding material provides a surface which mimics the in vivo surface of a fibrin clot.

i WO 93/11260 PCT/US92/09972

I

Method for Measuring Fibrinolytic Capacity Within Whole Human Plasma Field of the Invention This invention relates to a method for measuring the fibrinolytic capacity of whole plasma. In particular this invention utilizes an immobilized plasminogen binding material to provide a surface which mimics the in vivo surface of a fibrin clot and thus allows for a better measure of plasma's fibrinolytic capacity.

Background A blood clot or thrombus is normally formed in response to signals associated with a break or tear in the blood vessel wall and thus prevents excessive leakage of blood from the circulation. However, excessive growth of a thrombus can itself fill and occlude the vessel, causing a lack of local blood flow.

Thus, clotting must be a dynamic process of thrombus formation and breakdown, carefully balanced to seal the vessel wall without completely blocking its lumen.

A blood clot is formed by the process of coagulation, in which an abundant and very soluble circulating protein, fibrinogen, is converted into a much less soluble protein, fibrin, by the action of the enzyme thrombin. Fibrin polymerizes and becomes covalently crosslinked to form the matrix of a blood clot which entraps platelets, other cells and blood proteins within its meshwork. One of these proteins, plasminogen, later can be converted into an active enzyme, plasmin, through the action of other enzymes known as plasminogen activators. Plasmin catalyzes the proteolytic cleavage of fibrin at several sites leading to formation of soluble fibrin degradation products and thus can dissolve thrombi. It is well known that soluble polylysine or its derivatives can activate 1 ~b 7

W

,i o 8 i WO 93/11260 PCr/US92/O9972 1 i;: i

J

i p~ iS i~!

~)X

plasminogen. Allen, Thromb. Haemostas 47(1):41- 45(1982); Petersen, L.A. and Swenson, Biochemica Biophysica Acta, 883:313-325(1986).

The plasma components which signal plasmin formation are called the fibrinolytic system. When this system is not sufficiently active compared with that of coagulation, a prothrombotic condition results that can lead to thrombotic disease including coronary thrombosis, deep vein thrombosis, peripheral arterial occlusion, pulmonary embolism, occlusive stroke and av others. Physicians attempting to correct suchAimbalance may administer antithrombotic agents heparin or plasminogen activators).

In assessing the causes of clotting, clinicians will routinely wish to measure both coagulation parameters thrombin time, prothrombin time) and fibrinolytic parameters. The latter, or fibrinolytic potential of the plasma is a complex function of the concentrations of plasminogen, plasmin inhibitors, plasminogen activators and plasminogen activator inhibitors. Ultimately it is reflected in the ability of plasma to produce sustained plasmin activity. Its assessment is an essential part of planning the treatment of coagulation disorders and thrombotic 25 disease.

A number of tests have been developed to measure the fibrinolytic potential in or fibrinolysis of whole plasma. For example, Wun and Capuano have described one such a method. J. Biol. Chem., 260(8):5061-5066 (1985).

The Wun method detects the spontaneous fibrinolysis of plasma clots by following the lysis of clots formed in an 1 125 -fibrinogen-supplemented citrated plasma. Using this method Wun determines the amount of lysis over a period of days by centrifuging a patient's plasma sample and plotting the radioactivity present in the supernatant of the centrifugal sample against the _IL L 1Y~? lll~-~ ll~ WO 93/11260 PCT/US92/09972 3 radioactivity found in the sample overall. This method has the disadvantage of using 1 125 -fibrinogen, which is radioactive and which also has a very short shelf life.

Moreover, it requires long incubation periods taking several days to complete.

Another fibrinolytic assay commonly used to measure fibrinolysis is the fibrin plate lysis method, Astrup, T. and Darling, Acta Physiol. Scand., 4:45(1942). In this assay opaque plasma clots are artificially created on plates or petri dishes. Patient samples are then applied to the clots and clear lysis zones are formed and then examined. This assay has several difficulties associated with it. For example, clot lysis zones are difficult to quantify and the assay itself requires extremely long incubation times sometimes up to 24 hours. A more rapid version of this test was developed by Marsh and Gaffney. This version, however, requires addition of plasminogen, thus altering the natural composition of the patient sample. Marsh, NA. and Gaffney, Thrombos. Haemostas. (Stuttg.), 38: 3545(1977).

The euglobulin clot lysis time assay is also commonly used to test fibrinolytic potential. This assay is conducted by forming a clot in the euglobulin fraction of the patient sample and then visually determining how long it takes for that clot to be dissolved by certain of the patient's own enzymes.

While this assay has the advantage of being relatively fast, usually 60-120 minutes, it has the disadvantage of being a subjective test where the end point, ie., the clot lysis, is determined through visual inspection of the reaction by the technician. In addition, in preparing the euglobulin fraction, certain important inhibitors of the clot lysis process normally present in the patient sample are removed. Thus, the euglobulin I _r IL~ WO 93/11260 PCT/US92/09972 4 assay does not provide the clinician with a complete clinical profile of a patient.

Thus, a fibrinolytic assay is needed that will be fast, reliable and representative of the in vivo fibrinolytic processes of a patient.

Therefore it is an object of the present invention to create a fast and reliable screening assay to identify abnormalities in fibrin-dependent fibrinolytic activation. It is a further cbject of the present invention to develop an assay that will assist clinicians in evaluting and managing patients at risk for post-operative thromboembolic complications. It is a further object of the present invention to develop an assay which mimics the in vivo fibrinolytic processes of a patient.

Description of Figures Ficure 1. Figure 1 demonstrates the effect of the concentration of poly-d-lysine and molecular weight on absorbance.

Figure 2. Figure 2 lists examples of various chromogenic substrates that can be used to measure or quantitate the plasmin formed using the method of the present invention.

Figure 3. Figure 3 shows absorbance data for 2,4,6, trinitrobenzyl poly-d-lysine with plasma pools.

Fisure 4. Figure 4 shows the equation used to calculate the percent of Fibrinolytic Potential of plasma samples tested using one of the methods of the present invention. This %FP equation is: %FP Sample Plasma Absorbance x Reference Plasma Reference Plasma Absorbance Assigned Value Ficure 5. Figure 5 shows the %FP of patient plasma samples versus time pre, during and post cardiopulmonary bypass surgery.

4

I

i .i WO 93/11260 PCT/US92/09972 Figure 6. Figure 6 shows the %FP of patient plasma samples using4tfh method of present invention versus time pre, during and post liver transplant surgery.

Figure 7. Figure 7 shows the %FP of samples from patients with various diseases determined using tve c 0 method of the present invention.

Figure 8. Figure 8 shows the effect of "HEPSTRACT" (a tradename for heparinase, an enzyme that degrades heparin or heparinized samples) on heparinized plasma samples.

Summary of the Invention The present invention relates to a fibrinolytic assay which utilizes an immobilized plasminogen binding material, preferrably poly-d-lysine or a derivative thereof, to mimic the in vivo fibrin clot surface. The plasminogen binding material is applied to a solid-phase matrix or support in such a way that the support becomes coated with the plasminogen binding material. Plasma, containing all fibrinolytic factors, or control samples, are added to the coated support and incubated at about room temperature for a period of time sufficient to convert a portion of the plasminogen in the sample to plasmin. This incubation period can vary from about 2 to about 60 minutes but preferrably will be between about 5 and about 30 minutes. It should be noted that incubation for more than about 30 minutes can actually decrease the signal, probably due to autolysis by plasmin. The assay, however, can still be performed after more than 30 minutes of incubation provided that all samples are treated consistently. The amount of plasmin formed directly correlates to the fibrinolytic potential within the sample. The plasmin present can be quantified by any number of standard methods, such as use of a plasmin synthetic substrate with a A 35 fluorometric, chromogenic or radioactive label or by immunochemical measurement. Husby, R.M. and Smith, I Cl i i i iL L WO 93/11260 PCT/US92/09972 6 Seminars in Thrombosis and Hemostatis Vol.VI(3):173-314 (1980).

This assay is a significant improvement over the currently available fibrinolytic assays as it provides a much faster as little as about 5-30 minutes and more reliable screening assay for determining abnormalities in the fibrinolytic processes of patients.

Particularly, the assay of the present invention is superior to other currently available assays because it more accurately reflects the physiological condition of the patient. First, it is more accurate because the sample used contains all the fibrinolytic factors present in vivo. Moreover, the addition of exogenous fibrinolytic factors is not required in order to initiate the reaction as is required with other fibrinolysis tests. Second, it utilizes an immobilized plasminogen binding material. The advantage of an immobilized plasminogen binding material over the commonly used soluble materials such as soluble polylysine is that the immobilized plasminogen binding material provides an activation surface which mimics the surface of a blood clot as it exists in vivo thus permitting the fibrinolytic factors to assemble on the artificial surface much as they do on the surface of a blood clot. Moreover, the relative concentrations of the blood factors are increased by providing this artificial surface thus enabling the reaction to proceed without the addition of any extraneous eyzymes.

Detailed Description of the Invention In the assay of the present invention a solid phase matrix or support made of any material commonly used for immunoassays such as latex, glass fiber or nitrocellulose is coated with a plasminogen binding material. In the most preferred embodiment the plasminogen binding material is poly-d-lysine or a derivative of poly-d-lysine such as trinitrobenzoylated WO 93/11260 PC/US92/09972 7 poly-d-lysine or other comparable derivative. The method of the present invention can also utilize poly-llysine, however, the 1-isomer is not as efficient as the d-isomer because it is more readily degraded by plasmin.

Fibrin and denatured fibrinogen can also be used as the plasminogen binding material. The molecular weight of the polylysine used can vary widely as almost any length of polymer above about 50,000 daltons will suffice, but in the most preferred embodiment the polymer should have a molecular weight between about 140,000 to about 250,000 daltons, as shown in Figure 1.

The plasminogen binding material can be suspended in a buffer solution such as sodium phosphate, sodium borate, sodium bicarbonate buffer or any comparable buffer. The concentration of plasminogen binding material used to coat the solid support can also vary widely, however, in the most preferred embodiment the polylysine concentration will range between about pg/ml to about 100 pg/ml.

Incubation of the plasminbgen binding material with the solid support is accomplished by passive adsorption at temperatures ranging from about 2 0 C to about 25°C for a period of time ranging from about 5 minutes to about 24 hours. Following incubation excess reagent is removed by washing with a buffer solution. In the preferred embodiment the solution is an isotonic buffer containing a surfactant at a neutral pH, such as imidazole buffered saline. Although hyper- or hypotonic buffers, with or without surfactant and at acidic or basic pH, are also suitable.

Appropriate quantities of plasma samples or controls are then applied to the derivatized solid support and the natural fibrinolytic process is permitted to proceed. This incubation with sample can range between about 5 and about 60 minutes but in the most preferred embodiment the incubation time of sample I I ~L WO 93/11260 PCT/US92/09972 8 with derivatized support is between about 5 and about minutes and most preferably about 15 minutes. Excess sample or control is removed by washing with a buffer solution. In the preferred embodiment the solution is an isotonic buffer containing a surfactant at a neutral pH, such as imidazole buffered saline. Although hyperor hypotonic buffers, with or without surfactant and at acidic or basic pH are also suitable. The plasmin formed during the incubation remains bound to the coated j 10 support and is then quantitated using standard quantitation methods, such as methods that employ a plasmin specific synthetic or natural substrate chromogenically, fluorometrically or radioactively labelled. The plasmin specific substrate is applied to y 15 the activated solid support containing the samples and an indicator is released. This incubation with substrate can range between about 30 minutes to up to about 24 hours but in the preferred embodiment the incubation time is between about 30 minutes to 2 hours and most preferably about one hour. Huseby, R.M. and Smith, Seminars in Thrombosis and Hemostasis, Vol. VI(3):173-314 (1980). Some examples of such I substrates which can be used to quantitate the plasmin formed by the method of the present invention are set forth in Figure 2. Plasmin may also be quantitated immunochemically using a plasmin/ plasminogen antibody.

Harpel, J. Clin. Invest. 68:46-55 (1981).

The method of the present invention can also be used in kit format. Components of such a kit would include a plasminogen binding material coated micro-well titer plates, a lyophilized calibrator of normal plasma, a first lyophilized control of normal pooled plasma samples, a second lyophilized control of normal pooled plasma samples, a substrate buffer, a lyophilized substrate, a solution to terminate the substrate-plasmin reaction and a wash buffer. An example of the I WO 93/11260 PCY/US92/09972 components which a kit might include are as follows: poly-d-lysine coated microwells, 2x8 modules, 6 modules/frame, 96 tests/kit; calibrator (lyophilized), 100 5% of normal plasma, 1.0 mL/vial; 1 vial/kit; a first control (level I) (lyophilized), >80% of normal plasma, 1.0 mL/vial, 1 vial/kit; a second control (level II) (lyophilized), <40% of normal plasma, 1-P mL/vial, 1 vial/kit; substrate buffer, 12 mL/vial, 1 vial/kit; substrate (lyophilized), 1 mL/vial, 1 vial/kit; stop solution or solution to terminate the plasmin/substrate reaction, 6 mL/vial, 1 vial/kit and wash buffer, concentrated solution, 20 mL/vial, 1 vial/kit.

The assay system of the present invention may also be modified using specific antibodies to measure lipoprotein(a), tissue, lasminogen activator (tPA), plasminogen activatorsT (PAI), alpha-2antiplasmin/plasmin complex and tPA/PAI complex.

Functional assays to quantify tPA, PAI or alpha-2antiplasmin activity are also possible using synthetic substrates and immobilized polylysine.

FAMPLES

The method of the present invention can be further demonstrated by the following examples.

EXAMPLE L.

Microwell titer plates were coated with 10 gg/ml of poly-d-lysine (molecular weight ranging from 14o,000- 250,000 daltons) in 100 mM sodium bicarbonate buffer, pH Coating with poly-d-lysine was performed by passive adsorption at 40C for 24 hours. Excess polymer was removed by washing with imidazole buffered saline.

Approximately 100 ul of each plasma sample or control was then applied to the coated support. The samples were incubated for 15 minutes. Excess reagents were removed by washing three times with about 200 ul of imidazole buffered saline each time. The plasmin formed during the incubation was quantitated with a plasminry\ WO 93/11260 PCT/US92/09972 0 specific synthetic substrate, H-D-norleucyl-hexahydrotyrosyl-lysine-p-nitroanilide diacetate salt (but any lysine or arginine terminal peptide with any colorimetric or fluorimetric tag could be used), that contained a chromophoric leaving group, .p-nitroaniline.

About 100 Al of the substrate was added to each well and incubated at room temperature for 60 minutes. The released chromophore, p-nitroanilide, was quantified in a spectrophotometer capable of measuring absorbance at 405 nm. Conveniently, the assay was performed in a 96well microwell system and a microwell absorbance reader was used. The absorbance of samples and controls were compared with the absorbance of a normal reference plasma and reported in terms of a percent of the reference plasma.

EXAMPLE II.

"A/S Nunc Maxi Sorp" microwell titer plates, 2x8 modules or equivalent, were coated with 20 Mg/ml of Scaltons poly-d-lysine (mean Molecular Weight of 248,400) in 0.1N sodium bicarbonate buffer, pH 9.0. Each well was filled with 110 ul of the poly-d-lysine solution and incubated for 4 hours at ambient or room temperature.

Approximately 110 ul of a 6% w/v fish gelatin/water solution was then added to the wells and incubated at ambient or room temperature for about 30 minutes. A 6% w/v solution was used for purposes of this Example, however, other variations may be used. The contents of the well were then aspirated and 250 ul/well of a solution containing 20 nM Tris, 80 mM Sodium Chloride and 0.02% "gween 20" pH 7.4, was added to each well as a wash. The wash solution was then aspirated and the wash procedure repeated twice. The wells were then air dried in a low humidity chamber for approximately 20 hours (humidity about 8-20%, temperature about 27-35oC.).

Approximately 100 ul each of plasma sample or control a Q\ was then applied to the coated support. The samples

I

WO 93/11260 PCT/US92/09972 were incubated for about 15 minutes. Excess reagents were removed by washing three times with about 200 ul of imidazole buffered saline each time. The plasmin formed during the incubation was quantitated with a plasminspecific synthetic substrate, H-D-norleucylhexahydrotyrosyl-lysine-p-nitroanilide diacetate salt (but any lysine or arginine terminal peptide with any colorimetric or fluorimetric tag could be used), that contained a chromophoric leaving group, p-nitroanilide.

About 100 ~l of the substrate was added to each well and incubated at room temperature for 60 minutes. The released chromophore, p-nitroaniline, was quantified in a spectrophotometer capable of measuring absorbance at 405 nm. Conveniently the assay was performed in a microwell system and a microwell absorbance reader was used. The absorbance of samples and controls were compared with the absorbance of a normal reference plasma and reported in terms of a percent of the reference plasma.

EXAMPLE III A 2,4,6-trinitrobenzyl (TNB) poly-d-lysine was prepared by incubating 20 mgs of poly-d-lysine (mean Molecular Weight of 160,009) with 13.2 umole of 2,4,6 trinitrobenzyl sulphonic acid in 4 mls of distilled water for 10 minutes at ambient or room temperature.

Unreacted 2,4,6 trinitrobenzyl sulphonic acid was removed by dialysis. The alkylation can be increased or decreased to provide fewer or more lysine residues respectively.

Microwell titer plates were coated with 10 pg/ml of poly-d-lysine (mean molecular weight 143,700) in 0.1 M sodium bicarbonate buffer, pH 9.5 or 10 ig/ml of TNBpoly-d-lysine (mean molecular weight 160,009) in 0.1 M sodium bicarbonate buffer, pH 9.5. Coating was performed by passive adsorption at 2-8°C for 24 hours.

S/ Excess polymer was removed by washing with 20 mM Tris i <cz WO 93/11260 PCT/US92/09972 12 buffercontaining 80 mM sodium chloride and a surfactant (.02%.Twee-20). Approximately 100 ul of a normal plasma pool sample was applied to the coated support.

'he samples were incubated for 15 minutes at room temperature. Excess reagents were removed by washing three times with about 200 ul of phosphate buffered saline. The plasmin formed during the incubation was quantitated with a plasmin specific substrate that contains a chromophoric leaving group, H-D-norleucyl- CHA-arginine-nitroanilide diacetate salt (but could be any lysine or arginine terminal peptide with any colorimetric or fluorimetric tag). About 100 uL of the substrate was added to each well and incubated at room temperature. Readings of the released chromophore, pnitroaniline, were quantified in a spectrophotometer capable of measuring the absorbance at 405 nm. The readings were taken after 15, 30, 60 and 120 minutes of incubation time. Conveniently the assay is performed in a 96-well microwell system and a microwell absorbance reader is used. The absorbance of samples using the TNB poly-d-lysine coated wells was compared to the absorbance of the same samples using the poly-d-lysine coated wells. Data is shown in Table I of Figure 3.

EXAMPLE IV Example III was repeated, except that the plasma pool samples were incubated with the coated wells for minutes. Data is shown in Table II of Figure 3.

EXAMPLE V Example III was repeated, except that the plasma pool samples were incubated with the coated wells for minutes. Data is shown in Table III of Figure 3.

When using a chromogenically or fluorometrically labelled substrate as in the above Examples, the Fibrinolytic Potential (FP) of the sample or control is measured using the following equation: s Ftr WO 93/11260 PCT/US92/09972 13 %FP Sample Plasma Absorbance x Reference Plasma Reference Plasma Absorbance Assigned Value In this equation the "Sample Plasma Absorbance" .is the absorbance value for the chromophoric or fluorogenic substance released in the reaction used to determine plasmin concentration in testing a plasma sample according to the method of the present invention. The "Reference Plasma Absorbance" is the absorbance value of the chromophoric or fluorogenic substance released in the reaction used to determine plasmin concentration in testing a reference or control sample according to the method of the present invention. The value assigned to the "Reference Plasma" can be determined from multiple assays against a 30 donor pool of fresh, normal plasma.

The mean absorbance value of the fresh donor pool is assumed to represent 100% fibrinolytic potential. The fibrinolytic potential is generally calculated from results of a minimum of 96 determinations (sixteen determinations from each of six randomly selected fivevial pools). Figure 4 shows the application of this equation to patient and reference samples.

Figures 5, 6 and 7 show the %FP of patient plasma samples tested as compared with reference samples or controls using the method set out in Example II. These samples were obtained from patients that had undergone cardiopulmonary bypass and liver transplant surgery and from patients with various other debilitating diseases.

The determination of %FP in patients is particularly important as preliminary research studies show that the %FP is reduced in patients with angina, myocardial infarction, deep venous thrombosis, stroke, disseminated intravasculor coagulation and congestive heart disease. The FP value is also compromised during surgery in patients undergoing liver transplantation or cardiovascular bypass; although FP 1 WO93/11260 PCY/US92/09972 14 recovered to normal levels within 10 days post-surgery, the rate of recovery varies with each patient. Finally, Figure 8 shows the effect "Hepstract" (a tradenane for heparinase, an enzyme that degrades heparin or heparinized samples) in heparinized plasma samples.

RA1~ ITr_

Claims (8)

1. A method for determining or detecting the fibrinolytic capacity within whole plasma comprising: incubating a plasminogen binding material with a solid support for a sufficient period of time that the support becomes coated with the plasminogen binding material; removing excess plasminogen binding material; incubating a plasma sample or control with the coated support for a sufficient period of time for plasmin to be formed; removing excess sample or control; measuring the concentration of plasmin bound to the support.

2. A method for determining or detecting the fibrinolytic capacity within whole plasma comprising: incubating a poly-d-lysine or a derivative of poly-d-lysine with a solid support for a sufficient period of time that the support becomes coated with the poly-d-lysine or a derivative of poly-d-lysine; removing excess poly-d-lysine or a derivative of poly-d-lysine; incubating a plasma sample or control with the coated support for a sufficient period of time for plasmin to be formed; removing excess sample or control; measuring the concentration of plasmin bound to the support. WO 93/11260 PCT/US92/09972 16

3. A method for determining or detecting the fibrinolytic capacity within whole plasma comprising: incubating a plasminogen binding material with a solid support for a sufficient period of time that the support becomes coated with the plasminogen binding material; adding a fish gelatin/water solution to the incubation mixture; removing the excess plasminogen binding material and the fish gelatin/water solution from the support; incubating a plasma sample or control with the coated support for a sufficient period of time for plasmin to be formed; removing excess sample or control; measuring the concentration of plasmin bound to the support.

4. A method for determining or detecting the fibrinolytic capacity within whole plasma comprising: incubating a plasminogen binding material with a solid support for a sufficient period of time that the support becomes coated with the plasminogen binding material; adding a fish gelatin/water solution to the incubation mixture; removir." the excess plasminogen binding material and fish gelatin/water solution from the support; washing the support with a buffer solution; removing the buffer solution from the support; incubating a plasma sample or control with the coated support for a sufficient period of time for plasmin to be formed; removing excess sample or control; WO 93/11260 PCT/US92/09972 17 adding a plasmin specific synthetic substrate to the support; and measuring the concentration of indicator formed.

The method of Claims 1, 3 and 4 wherein the plasminogen binding material is selected from a group consisting of poly-l-lysine, poly-d-lysine, a poly-d-lysine derivative, fibrinogen or fibrin.

6. The method of Claim 2 wherein the amount of poly-d- lysine or a derivative of poly-d-lysine added to said support is about 5 pg/ml to about 100 gg/ml

7. The method of Claim 2 wherein the poly-d-lysine or the poly-d-lysine derivative added to said support has a molecular weight of about 140,000 to about 250,000 daltons.

8. The method of Claims 1 or 2 wherein the concentration of plasmin bound to the support is measured using a synthetic substrate that contains a chromophoric leaving group.